1. Mayeux R:Epidemiology of neurodegeneration.Ann Rev Neurosci 2003, 26:81–104.
2. de Lau LM:Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study.Neurology 2004, 63:1240–1244.
3. Of importance Rao J:Neurochemistry of nigral degeneration. InHandbook of Parkinson’s Disease. Edited by Pahwa R, Lyons KE. New York: Futura; 2007: In press. A review of molecular mechanisms that may make the ventral tier of dopaminergic neurons of substantia nigra pars compacta more vulnerable to degeneration than the ventral tegmental area dopaminergic neurons.
4. Of major importance Rao J:Neurochemistry of Parkinson’s disease. InParkinson’s Disease and Related Disorders. Handbook of Clinical Neurology Series. Edited by Koller WC, Malamed E. New York: Elsevier; 2007: In Press. A detailed discussion of neurochemical changes in dopaminergic and nondopaminergic systems in PD.
5. Rascol O:A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group.N Engl J Med 2000, 342:1484–1491.